Laurus Labs Gelecekteki Büyüme
Future kriter kontrolleri 3/6
Laurus Labs kazanç ve gelirin sırasıyla yıllık 19.1% ve 13.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 18.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.7% olacağı tahmin edilmektedir.
Anahtar bilgiler
19.1%
Kazanç büyüme oranı
18.39%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 16.6% |
| Gelir büyüme oranı | 13.3% |
| Gelecekteki özkaynak getirisi | 18.73% |
| Analist kapsamı | Good |
| Son güncelleme | 20 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Apr 30
LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside
Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.Anlatı Güncellemesi • Apr 15
LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside
Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.
Anlatı Güncellemesi • Apr 01
LAURUSLABS: Currency And Execution Uncertainties Will Likely Cap Margin Upside
Analysts have made a small upward tweak to the Laurus Labs fair value estimate, with the price target moving from ₹540.28 to ₹543.09. This reflects updated assumptions on revenue growth and profitability.Anlatı Güncellemesi • Mar 18
LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks
Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.Anlatı Güncellemesi • Mar 04
LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside
Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.
Anlatı Güncellemesi • Feb 18
LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions
Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.Anlatı Güncellemesi • Feb 03
LAURUSLABS: Future Returns Will Depend On Confidence In Rich P E Assumptions
Analysts have lifted their fair value estimate for Laurus Labs from ₹863.13 to ₹913.47, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples, consistent with recent upward target revisions seen in related Street research. Analyst Commentary Bullish analysts point to the higher fair value estimate of ₹913.47 as support for a more constructive view on Laurus Labs, even though inputs are only slightly adjusted.Analiz Makalesi • Jan 28
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...Analiz Makalesi • Jan 25
Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing
With a price-to-earnings (or "P/E") ratio of 65.1x Laurus Labs Limited ( NSE:LAURUSLABS ) may be sending very bearish...Anlatı Güncellemesi • Jan 20
LAURUSLABS: Future Returns Will Depend On Rich P E Assumptions Holding
Analysts have lifted their price target for Laurus Labs to ₹863 from about ₹822, reflecting updated assumptions on fair value, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as a sign that current assumptions on Laurus Labs' fair value leave room for upside if the company executes consistently on profitability.Anlatı Güncellemesi • Jan 06
LAURUSLABS: Interim Dividend And Higher P E Multiple Will Support Upside
Analysts have raised their price target on Laurus Labs from ₹1,025 to ₹1,280, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News The Board of Directors approved an interim dividend of ₹0.80 per equity share of face value ₹2 for the 2025-26 financial year at the meeting held on October 23, 2025 (company filing).Anlatı Güncellemesi • Dec 21
LAURUSLABS: Interim Dividend May Not Offset Softer Margins Ahead
Analysts have moderately raised their price target on Laurus Labs from ₹303.09 to ₹330.21, citing a slightly higher justified valuation multiple that more than offsets their marginally softer assumptions on revenue growth and profit margins. What's in the News The Board approved an interim dividend of INR 0.80 per equity share (40 percent of the face value of INR 2) for FY 2025-26, signaling confidence in cash flows and shareholder returns (company filing).Anlatı Güncellemesi • Dec 07
LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks
Analysts have modestly increased their price target for Laurus Labs while maintaining fair value at ₹821.93, citing expectations of sustained earnings growth supported by a solid balance sheet, margin expansion, and revenue momentum from new market opportunities. Analyst Commentary Street research on comparable growth stories in the education and healthcare sectors highlights themes that are directly relevant for Laurus Labs, particularly around how markets price in multi year earnings expansion, balance sheet strength, and scalability in new markets.Anlatı Güncellemesi • Nov 23
LAURUSLABS: Future Revenue Upside May Be Limited By Execution Risks
Analysts have raised their price target for Laurus Labs slightly, from ₹815.86 to ₹821.93. They cite expectations of stronger revenue growth supported by a robust balance sheet and expanding opportunities in new markets.Anlatı Güncellemesi • Nov 04
LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.Analiz Makalesi • Oct 30
Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80
Laurus Labs Limited ( NSE:LAURUSLABS ) will pay a dividend of ₹0.80 on the 22nd of November. Even though the dividend...Anlatı Güncellemesi • Oct 21
Analysts Cite Growth Momentum and Strong Balance Sheet in Raising Laurus Labs Valuation Estimates
Analysts have raised their fair value estimate for Laurus Labs from ₹694.85 to ₹724.14. They cite continued revenue growth momentum and a strong balance sheet as key drivers for this upward revision.Analiz Makalesi • Oct 19
With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For
Laurus Labs Limited's ( NSE:LAURUSLABS ) price-to-sales (or "P/S") ratio of 8.2x may look like a poor investment...Analiz Makalesi • Aug 31
Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jul 20
Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%
The Laurus Labs Limited ( NSE:LAURUSLABS ) share price has done very well over the last month, posting an excellent...Analiz Makalesi • Jun 11
Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings
Unsurprisingly, Laurus Labs Limited's ( NSE:LAURUSLABS ) stock price was strong on the back of its healthy earnings...
Yeni Anlatı • Jan 26
CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams
Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 3/31/2029 | 102,621 | 15,804 | 6,088 | 16,669 | 6 |
| 3/31/2028 | 90,215 | 13,716 | 3,695 | 15,860 | 14 |
| 3/31/2027 | 78,928 | 11,074 | 1,234 | 13,655 | 11 |
| 3/31/2026 | 68,129 | 8,888 | 5,536 | 16,235 | N/A |
| 12/31/2025 | 67,216 | 8,433 | N/A | N/A | N/A |
| 9/30/2025 | 63,584 | 6,840 | 7,696 | 16,375 | N/A |
| 6/30/2025 | 59,286 | 5,088 | N/A | N/A | N/A |
| 3/31/2025 | 55,540 | 3,583 | -393 | 6,017 | N/A |
| 12/31/2024 | 52,733 | 2,003 | N/A | N/A | N/A |
| 9/30/2024 | 50,532 | 1,311 | -3,277 | 2,489 | N/A |
| 6/30/2024 | 50,540 | 1,482 | N/A | N/A | N/A |
| 3/31/2024 | 50,408 | 1,606 | -126 | 6,657 | N/A |
| 12/31/2023 | 49,821 | 1,879 | N/A | N/A | N/A |
| 9/30/2023 | 53,320 | 3,678 | 2,870 | 12,248 | N/A |
| 6/30/2023 | 56,834 | 5,637 | N/A | N/A | N/A |
| 3/31/2023 | 60,406 | 7,901 | 37 | 9,939 | N/A |
| 12/31/2022 | 60,845 | 9,176 | N/A | N/A | N/A |
| 9/30/2022 | 55,684 | 8,683 | 13 | 8,393 | N/A |
| 6/30/2022 | 51,960 | 8,374 | N/A | N/A | N/A |
| 3/31/2022 | 49,356 | 8,275 | 343 | 9,111 | N/A |
| 12/31/2021 | 49,227 | 8,937 | N/A | N/A | N/A |
| 9/30/2021 | 51,823 | 10,128 | -1,705 | 7,112 | N/A |
| 6/30/2021 | 51,177 | 10,532 | N/A | N/A | N/A |
| 3/31/2021 | 48,135 | 9,836 | 442 | 7,330 | N/A |
| 12/31/2020 | 42,407 | 7,971 | N/A | N/A | N/A |
| 9/30/2020 | 36,819 | 5,977 | 1,548 | 5,427 | N/A |
| 6/30/2020 | 32,555 | 4,120 | N/A | N/A | N/A |
| 3/31/2020 | 28,317 | 2,553 | 1,252 | 3,474 | N/A |
| 12/31/2019 | 26,277 | 1,883 | N/A | N/A | N/A |
| 9/30/2019 | 24,276 | 1,326 | N/A | 3,538 | N/A |
| 6/30/2019 | 23,035 | 923 | N/A | N/A | N/A |
| 3/31/2019 | 22,919 | 938 | N/A | 2,977 | N/A |
| 12/31/2018 | 22,170 | 957 | N/A | N/A | N/A |
| 9/30/2018 | 21,665 | 1,127 | N/A | N/A | N/A |
| 6/30/2018 | 21,168 | 1,453 | N/A | N/A | N/A |
| 3/31/2018 | 20,562 | 1,676 | N/A | 3,425 | N/A |
| 12/31/2017 | 19,687 | 1,917 | N/A | N/A | N/A |
| 9/30/2017 | 19,954 | 2,019 | N/A | N/A | N/A |
| 6/30/2017 | 19,733 | 2,014 | N/A | N/A | N/A |
| 3/31/2017 | 19,046 | 1,881 | N/A | 3,320 | N/A |
| 3/31/2016 | 17,776 | 1,337 | N/A | 1,820 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: LAURUSLABS 'nin tahmini kazanç büyümesi (yıllık 19.1% ) tasarruf oranının ( 6.9% ) üzerindedir.
Kazançlar ve Piyasa: LAURUSLABS şirketinin kazançlarının (yıllık 19.1% ) Indian pazarından (yıllık 16.3% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: LAURUSLABS şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.
Gelir ve Pazar: LAURUSLABS şirketinin gelirinin (yıllık 13.3% ) Indian pazarından (yıllık 10.8% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: LAURUSLABS şirketinin gelirinin (yıllık 13.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: LAURUSLABS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.7 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 13:32 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Laurus Labs Limited 22 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Ashwin Mehta | Ambit Capital |
| null null | Antique Stockbroking Ltd. |